Meredith McKean, MD, MPH
Specialities
- Melanoma
- Skin cancer
- Clinical trials and research advancements
- Early-phase drug development
Education
Medical Degree: University of Iowa  Â
Residency: University of Colorado Â
Fellowship: University of Texas MD Anderson Cancer Center  Â
Location
335 24th Avenue North, Suite 200 Â
Nashville, Tennessee 37203Â
Phone: 615-329-7640Â
Fax: 615-234-7723Â
Language
English
Biography
Dr. McKean is a board-certified medical oncologist at SCRI Oncology Partners and serves as the director of the Melanoma and Skin Cancer Research Program at SCRI. In addition to her medical degree, Dr. McKean also holds a Master of Public Health degree from the University of Iowa. Dr. McKean joined SCRI after completing her fellowship in oncology and hematology at the University of Texas MD Anderson Cancer Center. In 2017, she received the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award.
Philosophy
Dr. McKean is passionate about advancing treatment for skin cancer and providing access to the latest innovations in care. She works with each patient to design a treatment plan that best meets their unique needs.
Relevant Research
Cancer Discovery
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Journal of Clinical Oncology
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
The Lancet
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study